Abstract: A 41-year-old male with erythrodermic psoriasis treated with secukinumab was reported and the related literature were reviewed. After excluding hepatitis and tuberculosis, the patient was given the secukinumab with informed consent. The dose was 300 mg subcutaneously once a week in the first 4 weeks, then 300 mg once every four weeks. The PASI achieved to 75% at week 4 and 100% at week 8. There was no recurrence and adverse events after 32 weeks follow-up.

Key words: erythrodermic psoriasis, secukinumab, psoriasis, biologics, anti-IL17A